This approach undermines the real intent of the legislation.
Editor's note · Context
Barton criticizes CMS's reimbursement strategy for biosimilars.
Share & report
More from Joe Barton
I think it enhances transparency and the confidence of the American people as we do rulemaking.
This is a very complicated issue. The average person doesn't understand the difference between a New Source Review or whatever else we are talking about here.
Mr. Chairman, we have a great piece of legislation before us today. Chairman Walden and Ranking Member Pallone have been great leaders in shepherding dozens of opioid-related bills through the Energy and Commerce Committee. This particular…
Mr. Chairman, I can't think of a more unrewarding, difficult, fruitless issue to be asked to be the leader on than trying to find a solution to high-level nuclear waste. Can you imagine if, when you get elected to Congress, you are called…





